GV returned to reinvest in small molecule drug developer Ventus Therapeutics having backed its $60m series A round almost a year ago.

US-based small molecule drug developer Ventus Therapeutics completed a $100m series B round yesterday featuring GV, a corporate venture capital subsidiary of internet and technology group Alphabet. Investment manager RA Capital Management led the round, which included Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities, as well as…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.